182 related articles for article (PubMed ID: 16859314)
1. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
2. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
Pasha FA; Muddassar M; Neaz MM; Cho SJ
J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
[TBL] [Abstract][Full Text] [Related]
6. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
7. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
9. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
11. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.
Supino R; Polizzi D; Pavesi R; Pratesi G; Guano F; Capranico G; Palumbo M; Sissi C; Richter S; Beggiolin G; Menta E; Pezzoni G; Spinelli S; Torriani D; Carenini N; Dal Bo L; Facchinetti F; Tortoreto M; Zunino F
Oncology; 2001; 61(3):234-42. PubMed ID: 11574780
[TBL] [Abstract][Full Text] [Related]
12. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
13. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
[TBL] [Abstract][Full Text] [Related]
15. The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Liang H; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2008 Apr; 16(7):3959-68. PubMed ID: 18258442
[TBL] [Abstract][Full Text] [Related]
16. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
17. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
19. Improvement of multivariate image analysis applied to quantitative structure-activity relationship (QSAR) analysis by using wavelet-principal component analysis ranking variable selection and least-squares support vector machine regression: QSAR study of checkpoint kinase WEE1 inhibitors.
Cormanich RA; Goodarzi M; Freitas MP
Chem Biol Drug Des; 2009 Feb; 73(2):244-52. PubMed ID: 19207427
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization.
Hartley JA; Reszka K; Zuo ET; Wilson WD; Morgan AR; Lown JW
Mol Pharmacol; 1988 Mar; 33(3):265-71. PubMed ID: 3352592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]